Revolutionizing Human Healthcare with Next-Generation Metagenome Sequencing
Dr. Maike Seifert, Head of unit at Karolinska Institute emphasized the potential transformative impact of next-generation metagenome sequencing on human healthcare. Her team’s work develops crucial biobanking resources and implements advanced genomic technologies for both clinical practice and drug development.
- Comprehensive microbiome research and biobank development:
Dr. Seifert discusses the establishment of the Center for Translational Microbiome Research at the Karolinska Institute to understand the microbiome’s influence on health and disease. The center has built a significant biobank of over 200,000 human samples, providing a rich resource for developing novel therapies in the fields of gastroenterology, reproductive health, and cancer. - Advancement in metagenome sequencing technology:
In response to the clear limitations of 16S sequencing for population studies, the center pivoted to more advanced sequencing techniques. This includes utilizing extensive automation of their internal processes. - Metagenomic method development and clinical applications:
Dr. Seifert’s team has standardized their metagenome sequencing processes across a range of sample types and developed new protocols that lower the minimum input requirements and enhances sensitivity through host DNA depletion. They have recently launched a major project called SweMaMi, aimed at the early detection of pregnancy-related complications through simple microbial assessment, underscoring the practical medical applications of their research.
